Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Freelancer

    MCap

    AUD77m

    Last close

    AUD0.19

    ▲ 0.02 (8.82%)

    Vection Technologies

    MCap

    AUD36m

    Last close

    AUD0.03

    ▲ 0.00 (7.41%)

    Amoeba

    MCap

    EUR33m

    Last close

    EUR0.70

    ▲ 0.04 (5.91%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Sareum Holdings (AIM: SAR)

Last close As at 18/11/2024

GBP0.25

— 0.00 (0.00%)

Market capitalisation

GBP31m

Sareum is a UK-based drug development company, specialising in small molecule kinase inhibitors. Its flagship programmes are its pre-clinical TYK2/JAK1 inhibitors, SDC-1801 for autoimmune diseases and SDC-1802 for cancer. SDC-1801 is undergoing advanced dose finding and toxicology studies with a target to file a CTA in mid-2021. Other programmes include the CHK1 inhibitor SRA737 (Sareum holds a 27.5% economic interest), previously out licensed to Sierra Oncology and the de-prioritised FLT3+Aurora kinase.

Latest Insights

View More

Healthcare | Update

Sareum Holdings — SDC-1801 prepping to enter Phase II

Healthcare | Flash note

Sareum Holdings — New funding extends runway to Phase II

Healthcare | Flash note

Sareum Holdings — SDC-1801 records positive Phase Ia data

Healthcare | Update

Sareum Holdings — A decisive period ahead for SDC-1801
Sareum Holdings_resized
Visit Website

Sector

Healthcare

Equity Analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Jyoti Prakash

Jyoti Prakash

Analyst, Healthcare

Arron Aatkar

Analyst

Key Management

  • John Reader

    CSO

  • Stephen Parker

    Chairman

  • Tim Mitchell

    CEO

Balance Sheet

Forecast net cash (£m)

0.5

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (15.5) (18.3) (59.2)
Relative (13.4) (16.3) (62.5)
52 week high/low 67.5p/10.2p

Financials

Sareum Holdings’ FY24 results summarised an active period for lead asset SDC-1801, a dual TYK2/JAK1 inhibitor, which successfully completed Phase I trials in Australia and is now undergoing preparatory work to commence Phase II studies, likely in psoriasis patients. The recently reported unblinded data noted robust pharmacokinetic (PK)/pharmacodynamic (PD) properties and reiterated the drug’s desirable safety profile. While Sareum had previously proposed a smaller Phase Ib study, the plan has pivoted to running a larger Phase II trial, which requires a long-term (c 16 weeks) toxicology study before initiation. Sareum recently secured £3.4m in equity funding and a further c £1m in R&D tax credits, which management believes will be sufficient to complete the Phase II preparatory activities and fund preclinical work on its second asset, SDC-1802. We believe Sareum will be seeking partnering opportunities to support Phase II development of SDC-1801.

Research

Flash note

Healthcare

Sareum Holdings — New funding extends runway to Phase II

Flash note

Healthcare

Sareum Holdings — SDC-1801 records positive Phase Ia data

Healthcare

Update

Sareum Holdings — SDC-1801 prepping to enter Phase II
View All

Thematics

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free